|
Edited on Thu Mar-04-10 11:42 AM by bik0
Drug companies argue they have to charge high prices for new drugs to recoup R&D expense and the cost of clinical trials. It takes at about 10 years from inception to FDA approval and only 1-2% of all drugs that go to trials ever get approved. But what is also skewing the prices here in the U.S. is drug companies have to negotiate directly with governments with nationalized health care (Canada, France, U.K. etc.) and as a result, those countries negotiate heavy discounts and then the drug companies turn around and raise their prices to U.S. insurance companies and health care providers so it all averages out and normalizes their profit structure. As tough as it is to come up with a drug that works, another issue is the FDA approves expensive treatments that only extend life for a few month or only work on a small percentage of the population. How valuable is life? Is it so valuable that any treatment at any cost is worth it to keep someone alive for a few more days or weeks. That sounds noble but is it fair to the general population who have to pick up the tab through higher premiums and taxes? Some snips from an eye opening account of someone who analyzed the cost of care for a dying loved one… ‘Any Soldier’ The entire medical bill for seven years, in fact, was steeply discounted. The $618,616 became $254,176 when the insurers paid their share and imposed their discounts. Of that, Terence and I were responsible for $9,468 -- less than 4 percent.
The bills and records document our renewed fight as summer in Philadelphia turned to autumn. Terence resumed Avastin. Because he wasn’t in a clinical trial, our insurance company was billed: $27,360 a dose, for four treatments, more than the cost of the surgery to remove his kidney in 2000.
I learned that over the years of Terence’s battle with cancer, some insurers drove harder bargains than others. In December 2006, for example, UnitedHealthcare, a unit of UnitedHealth Group Inc., paid $2,586 to the University of Pennsylvania hospital for a chest scan; in March 2007, after I switched employers, WellPoint Inc.’s Empire Blue Cross & Blue Shield paid $776 for the same $3,232 bill.
In just the last four days of trying to keep him alive -- two in intensive care, two in a cancer ward -- our insurance was charged $43,711 for doctors, medicines, monitors, X-rays and scans. Two years later, the only thing I know for certain that money bought was confirmation that he was dying.
Some of the drugs probably did Terence no good at all. At least one helped fewer than 10 percent of all those who took it. Pharmaceutical companies and insurers will have to sort out the economics of treatments that end up working for only a small subset. Should everyone have the right to try them? Terence and I answered yes. Each drug potentially added life. Yet that too led me to a question I can’t answer. When is it time to quit?
As I leafed through the stack of documents, it was easy to see why 31 percent of the money spent on health care goes to paperwork and administration, according to research published in 2003 by the New England Journal of Medicine. That number has either stayed the same or grown, said Dr. Steffie Woolhandler, a professor at Harvard Medical School and a co-author of the study cited by the journal. Some bills took days to decipher. What did “opd patins t” or “bal xfr ded” mean? How could I tell if the dose charged was the same as the dose prescribed?
The documents revealed an economic system in which the sellers don’t set and the buyers don’t know the prices. The University of Pennsylvania hospital charged more than 12 times what Medicare at the time reimbursed for a chest scan. One insurer paid a hospital for 80 percent of the $3,232 price of a scan, while another covered 24 percent. Insurance companies negotiated their own rates, and neither my employers nor I paid the difference between the sticker and discounted prices.
‘It’s Completely Insane’ In this economic system, prices of goods and services bear little relation to the demand for them or their cost to make -- or, as it turns out, the good or harm they do. “No other nation would allow a health system to be run the way we do it. It’s completely insane,” said Uwe E. Reinhardt, a political economy professor at Princeton University, who has advised Congress, the Veteran’s Administration and other agencies on health-care economics.
http://goo.gl/tufp
|